International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
Phone760-940-6383
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.46 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/9/2019 (Estimated)
OptionableNot Optionable
International Stem Cell (OTCMKTS:ISCO) Frequently Asked Questions
What is International Stem Cell's stock symbol?
International Stem Cell trades on the OTCMKTS under the ticker symbol "ISCO."
How were International Stem Cell's earnings last quarter?
International Stem Cell Corp (OTCMKTS:ISCO) released its quarterly earnings results on Thursday, November, 15th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter. The biotechnology company earned $3.20 million during the quarter. International Stem Cell had a negative net margin of 23.26% and a negative return on equity of 123.16%. View International Stem Cell's Earnings History.
When is International Stem Cell's next earnings date?
Has International Stem Cell been receiving favorable news coverage?
Media headlines about ISCO stock have trended somewhat positive recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. International Stem Cell earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of International Stem Cell's key competitors?
Some companies that are related to International Stem Cell include MGC Pharmaceuticals (MXC), BIOLINERX LTD/S (BLRX), Viridium Pacific Group (VIR), Indiva (NDVA), Lexagene (LXG), OmniComm Systems (OMCM), Celsion (CLSN), Avacta Group (AVCT), Leap Therapeutics (LPTX), TRACON Pharmaceuticals (TCON), Mannatech (MTEX), Obalon Therapeutics (OBLN), Zelda Therapeutics (ZLD), Helix Biopharma (HBPCF) and AIT Therapeutics (AITB).
What other stocks do shareholders of International Stem Cell own?
Who are International Stem Cell's key executives?
International Stem Cell's management team includes the folowing people:
- Prof. Andrey Semechkin, Co-Chairman & CEO (Age 59)
- Dr. Russell Kern, Exec. VP, Chief Scientific Officer & Director (Age 33)
- Ms. Sophia Garnette J.D., VP of Legal Affairs & Operations and Sec. (Age 35)
- Mr. Francisco Bustamante, Pres of Lifeline Cell Technology LLC
How do I buy shares of International Stem Cell?
Shares of ISCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is International Stem Cell's stock price today?
One share of ISCO stock can currently be purchased for approximately $1.4990.
How big of a company is International Stem Cell?
International Stem Cell has a market capitalization of $11.29 million and generates $7.46 million in revenue each year. The biotechnology company earns $-6,060,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.
What is International Stem Cell's official website?
How can I contact International Stem Cell?
International Stem Cell's mailing address is 5950 PRIESTLY DRIVE, CARLSBAD CA, 92008. The biotechnology company can be reached via phone at 760-940-6383 or via email at [email protected]
MarketBeat Community Rating for International Stem Cell (OTCMKTS ISCO)
MarketBeat's community ratings are surveys of what our community members think about International Stem Cell and other stocks. Vote "Outperform" if you believe ISCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
